An expert discusses the need to tailor treatment duration in bladder cancer, balancing improved outcomes with toxicity and ...
A phase 2 study evaluated the efficacy and safety of adding pembrolizumab to trimodal therapy as a bladder-sparing approach for muscle-invasive bladder cancer (MIBC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results